The spectrum of entities, the therapeutic strategy and the outcome of mature aggressive B-cell Non-Hodgkin lymphomas (maB-NHL) differs between children and adolescents on the one hand and adult patients on the other. Whereas adult maB-NHL have been studied in detail, data on molecular profiling of pediatric maB-NHL are hitherto lacking. We analyzed 65 cases of maB-NHL from patients up to 18 years of age by gene expression profiling, matrix CGH, FISH and immunohistochemistry. The majority of the analyzed pediatric patients were treated within prospective trials (n=49). We compared this group to a series of 182 previously published cases of adult maB-NHL.
Introduction
Lymphomas are the third most common group of cancers in children and adolescents. Non-Hodgkin lymphomas (NHL), which account for approximately 60% of all lymphomas, represent 6% of all malignancies in children up to 14 years of age (German Childhood Cancer Registry, GCCR, http://info.imsd.unimainz.de/K_Krebsregister/english/). The spectrum of NHL occurring in children and adolescents differs strikingly from adults. Whereas indolent lymphomas are frequent in adults, the vast majority of lymphomas in children and adolescents are aggressive lymphomas, mainly mature aggressive B-cell lymphomas (maB-NHL) including particularly Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) 1 
.
With currently available combination chemotherapy for both BL and DLBCL an overall survival (OS) rate of 90% and more can be reached in children 2; 3 . In most pediatric study groups BL and DLBCL, although recognized by the WHO classification as distinct lymphoma entities, are currently treated according to the same treatment protocols in children [2] [3] [4] . The stratification of treatment intensity is based on clinical risk factors like stage and LDH, but not on the histopathological diagnosis. In adults, only BL is treated with protocols derived from those used in children 5; 6 . However, for DLBCL CHOP-like regiments are the standard for adult patients 2; 3; 7; 8 .
For personal use only. on . by guest www.bloodjournal.org From Gene expression profiling can be used to classify maB-NHL into BL and DLBCL more precisely than it is possible with the criteria of the WHO classification, which are based on morphology, immunophenotype and genetics 9; 10 . Using this molecular approach, we and other groups were able to recognize a subgroup of lymphomas described as "molecular BL" (mBL) and to separate these from nonmBL, a group which is mainly composed of DLBCL, leaving a set of yet unclassifiable (intermediate) lymphomas 9; 10 . In adult DLBCL, gene expression and genomic profiling indicated the existence of several biological subgroups which might explain the clinical heterogeneity of the disease 11; 12 . Using a immunohistochemical classifier, we showed recently that pediatric DLBCL are predominantly lymphomas of the germinal center subtype (GCB) which, in contrast to their adult counterpart, are virtually devoid of the translocation t(14;18). These findings indicate that pediatric DLBCL might be a more homogeneous disease than adult DLBCL 13 . Based on our previous results, we hypothesised that mBL occur in pediatric and adult patients but subtle molecular differences between pediatric and adult lymphomas might explain clinical differences such as the gender distribution. To gain further insights into the molecular characteristics of pediatric B-NHL, we performed molecular profiling, including gene expression analysis, matrix-CGH, interphase fluorescence in situ hybridization (FISH) and immunohistochemistry on a series of 65 maB-NHL from patients diagnosed at an age of less than ≤18 years, including 54 patients ≤14 years. Of the latter, 49 were treated within For personal use only. on June 9, 2017. by guest www.bloodjournal.org From prospective clinical trials of the German NHL-BFM study group. We compared the pediatric cohort to 182 maB-NHL in adults. Our data provide new insights into the biology of pediatric maB-NHL and might help to design future therapeutic strategies.
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Material and Methods

Patients
We analyzed a total of 65 maB-cell lymphomas from patients ≤18 years, 29 of whom had been already included in a previously published series but have not been analyzed under the aspects presented. A total of 36 lymphomas were newly analysed herein (supplementary figure S1 and S2) 9 . Since BL are much rarer than DLBCL, the efforts to collect BL were stronger than to collect non-BL/DLBCL in our previous study which was focussing of the differences between both entities independent of the patient age 9 . Therefore, the percentage of BL selected for molecular analysis was higher in our previous study 9 Lymphomas, for which no consent for a classification according to WHO was found, were designated as B-NHL high-grade. The reasons for lacking consent among the specialists were ambiguous morphological characteristics of the lymphoma or insufficient quality for a morphological evaluation 9 . The pathology review was done on H&E or Giemsa stained slides with the use of immunohistochemical stainings which included CD20, BCL2 and Ki-67. At the time of the review sessions the pathologists were neither aware of the age of the patient nor of any information concerning genetic alterations. The review was done on several sessions in which adult and pediatric lymphomas were mixed.
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From All specimen analyzed in our published series 9 and the newly analyzed series herein had a tumor cell content of >70%.
Of the 65 patients, 54 were ≤14 years at diagnosis. Of those, 49 (91%) were treated within controlled clinical trials of the Berlin-Frankfurt-Muenster Groups (BFM) (supplementary figure S2) . A previously published series of 182 aggressive maB-NHL in adult patients served as a control group 9 . The study was performed as part of the "Molecular Mechanisms in Malignant Lymphomas"
Network Project of the Deutsche Krebshilfe for which central and local ethics approval was obtained.
Informed consent was provided according to the Declaration of Helsinki.
Immunohistochemistry and Fluorescence in situ hybridization (FISH)
Immunohistochemistry and FISH were performed and evaluated using standard protocols. Antibodies and FISH probes applied have been described in detail in Hummel et al 9 .
Gene expression profiling Gene expression profiling using Affymetrix GeneChip U133A was performed as described recently 9 . The gene expression raw data were normalized by means of the variance-stabilizing procedure and summarization of probes within probe sets 15; 16 . To rank differentially expressed genes between pediatric and adult For personal use only. on June 9, 2017. by guest www.bloodjournal.org From mBL, microarray samples were measured by a two-sample t-score regularized by adding a constant fudge factor to the denominator. Statistical significance was assessed by calculating p-values based on 1000 random permutations of the class labels and subsequently estimating false discovery rates (FDR) based on the distribution of these p-values 17 . The data discussed are available from the the Gene Expression Omnibus of the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/geo/) though GEO accession numbers GSE10172 (36 newly analyzed cases herein) and GSE4475 (cases described in 9 ).
Array comparative genomic hybridization (array CGH) DNA was extracted from frozen sections and CGH performed as described recently 9 . Every of the about 2800 BAC clones on a CGH-array was classified as a genomic gain, loss, normal copy number or a missing value 18 . A Chi-square test statistic was computed for each clone in order to test for a disproportionate number of genomic aberrations in a given subgroup of cases. Missing values were removed before computing each statistic. Multiple testing was performed with the step-down minP method implemented in the R package multitest 19 .
Statistical analyses
There exists no clear-cut age border between pediatric and adult lymphoma Chi-square, Fisher's exact and log-rank tests were applied to test for group differences. Survival was calculated from the day of diagnosis until death or until the date of last follow-up.
Results
Patient characteristics
In order to characterize the molecular spectrum of pediatric maB-NHL we performed molecular profiling in a series of 65 lymphomas from patients ≤18 years of age. Of the 54 patients ≤14 years, 49 (91%) were treated within controlled clinical trials of the Berlin-Frankfurt-Muenster Group (BFM), namely NHL-BFM 81 (n=1), BFM 83 (n= 2), 86 (n=7), 90 (n=14), 95 (n=24) and B-NHL BFM 04 (n=1). These trials include more than 90% of children diagnosed with NHL in Germany. There were no significant differences with regard to epidemiological, histological or clinical features between the subset analyzed herein and the overall population of 1325 patients included in the named BFMtrials (supplementary table S1 ). Thus, the present series can be regarded as representative for maB-NHL in the German pediatric population.
Molecular profiling of a novel series of 36 pediatric maB-NHL
A total of 36 pediatric lymphomas which were not part of our previous study 9 were newly profiled as part of this study. The lymphomas were molecularly classified into mBL and non-mBL based on the mBL index 9 . We did not detect any significant differences in gene expression and matrix CGH profiles comparing the cases from our old series to the cases newly analyzed herein (data not shown). Of the newly analyzed, 13 were classified as mBL, 14 as nonmBL leaving 9 unclassifiable intermediates (supplementary table S2). Of the 13 mBL all were IG-MYC positive and 11 were classified as MYC-simple, meaning that in addition to IG-MYC fusion no or only little additional genetic abnormalities were detectable 9 . On the other hand, only 1 of the 14 non-mBL carried the IG-MYC translocation. In this independent dataset these findings confirm the good agreement between the mBL index and the pattern of genetic aberrations, and thus the validity of our previously described mBL signature to distinguish BL from other maB-NHL 9 .
Molecular spectrum of maB-NHL in children Together, we molecularly profiled maB-NHL from a total of 65 patients ≤18 years in the present as well as our previous study 9 . The clinical and molecular characteristics of these lymphomas are shown in tables 1 and 2, respectively.
Among the 54 patients who were ≤14 years at presentation, the morphological diagnoses were BL (n=16, 30%), atypical BL (BL-like, n=10, 19%), DLBCL (n=16, 30%), follicular lymphoma (FL grade 3, n=2, 4%) and high-grade B-NHL not further classified (n=10, 19%, table 1). Gene expression profiling revealed 34 mBL (63%), 11 intermediates (20%) and 9 (17%) non-mBL lymphomas in the group of pediatric patients (table 2). Morphologic BL/atypical BL as well as mBL defined by gene expression were more frequent in children than adults (49% versus 11% and 63% versus 11%, respectively). Vice versa, DLBCL and nonmBL were less frequent in children than in adults (30% versus, 82% and 17% versus 67%, respectively). The percentages of molecularly unclassifiable cases For personal use only. on June 9, 2017. by guest www.bloodjournal.org From that were called "intermediates" 9 were similar in the two age groups (20% in children versus 22% in adults, table 2).
Two lymphomas were diagnosed morphologically as follicular lymphoma grade 3.
These two lymphomas were included in the study because the initial diagnosis before the review was maB-NHL. One of the two lymphomas was molecularly defined as mBL. Reanalysis of the histological slides suggest that this lymphoma might present a rare example of a follicular growing BL whereas the other lymphoma, a non-mBL presents a follicular lymphoma with transformation to a DLBCL.
Remarkably, of the 16 morphologically defined DLBCL in children, 5 (31%) were Compared to pediatric patients, a much stronger heterogeneity of the adult lymphoma with regard to biological features, clinical parameters and treatment modalities can be assumed. Nevertheless, we aimed at an initial molecular comparison between both mBL and non-mBL between children and adults.
Lymphomas classified as intermediate were not compared in detail between
org From children and adults as they do not constitute a separate group but merely represent unclassifiable cases.
Comparison of pediatric and adult mBL
We compared a total of 34 pediatric (<=14 years) and 20 adult (>18 years) mBL.
There were no significant differences between adults and children with respect to the expression of CD10, BCL-2, BCL-6 or Ki-67 detected by immunohistochemistry (supplementary table S4). Similarly, the genomic imbalances detected by array CGH were remarkably similar in pediatric (n=33) and adult (n=20) mBL (figure 2).
The mBL-signature genes (n=74 features) were selected with pediatric and adult patients as input. Hence, the mBL-index is not expected to differ between children and adults. However, we considered the whole transcriptome (>20.000 features) while comparing children and adult mBLs. For this purpose the gene expression profiles of pediatric and adult mBL were compared directly using regularized t-scores and empirical p-values computed by random permutations of the class labels. For this purpose the gene expression profiles of pediatric and adult mBL were compared directly using regularized t-scores and empirical pvalues computed by random permutations of the class labels. We were unable to find any evidence of significant differences in gene expression between the two groups (data not shown). Finally, we did not observe a significant difference in survival between pediatric and adult mBL treated with BFM or comparable BFor personal use only. on June 9, 2017. by guest www.bloodjournal.org From ALL-like protocols (5-year survival: 87% versus 70%, p=0.67) or any other significant differences in clinical characteristics except a trend for lower frequency of B-symptoms (supplementary table S5 ). Thus, with the exception of the well known marked male predominance characteristic for pediatric BL that is not present in adult BL (79% versus 55%, p=0.07), mBL seems to be a rather homogenous disease in children and adults considering the molecular and clinical features analysed herein.
As reported by us and others, some mBL display features that are considered uncommon for BL like BCL2 protein expression, Ki-67 index of <95% or a high genetic complexity 9; 10 . Figure 3 demonstrates, that these "uncommon" features of mBL also occur in pediatric patients. However, if mBL with at least one "uncommon" feature (n=17) were compared to mBL without "uncommon" features (n=17), no statistically significant differences were found of clinical features including overall survival (data not shown).
Comparison of pediatric and adult non-mBL Due to differences in therapy between children and adults with non-mBL, a direct comparison of survival is not feasible with the currently available data 9; 10 . Similarly, a direct comparison of gene expression or matrix-CGH profiles between subgroups of pediatric and adult non-mBL seemed not to be feasible because of the small pediatric sample size. Four of the non-mBL were assigned to the GCB type (44%) and 3 to the ABC type (33%) of DLBCL leaving 2 unclassified cases (22%). This distribution did not significantly differ from that in For personal use only. on June 9, 2017. by guest www.bloodjournal.org From adult cases. Analogous, we failed to detect any significant differences with regard to antigen expression between pediatric and adult non-mBL, though the power of these comparisons was of course limited by the low number of pediatric cases. , since the group of morphologically defined DLBCL in children seems to contain a higher rate of "contamination" with lymphomas with a mBL expression profile than their adult counterpart. Although adequate studies are lacking, initial reports suggest that morphologically defined DLBCL with an mBL gene expression signature might benefit from BL therapy protocols 9; 10; 25 . Since the therapeutic strategies in BL and DLBCL are the same in children, the problem of assigning a patient with a maB-NHL to an insufficient therapy based on the morphological/histopathological diagnosis is clinically less relevant in children than in adults at the current stage.
However, future targeted therapeutic strategies might need to be based on precise distinction of mBL from non-mBL. It should be taken into consideration that the morphological/histopathological diagnosis in our study was generated without knowledge of the age of the patient, which would otherwise influence morphological diagnostic decisions towards BL. Thus, these results challenge the morphological criteria for distinguishing BL and DLBCL in pediatric patients.
The GCB subtype of non-mBL shows a favourable outcome compared to the ABC subtype in adult patients 11 . Recent data suggested that morphologically defined DLBCL might differ between children and adults in their composition of For personal use only. on June 9, 2017. by guest www.bloodjournal.org From molecular subtypes with a higher proportion of the GCB subtype of DLBCL (based on assignment by means of immunohistochemistry) in the younger age group 13; 26 . In the light of our molecular profiling data, these differences might at least partially be explained by the high contamination of morphologically defined DLBCL by mBL in pediatric patients. Indeed, if gene expression profiling is applied, mBL are classified as the GCB subtype of DLBCL if this algorithm for DLBCL is used for mBL 9 . Using gene expression as the gold standard of DLBCL classification into ABC and GCB subtypes, we found that pediatric non-mBL showed only a moderate predominance of the GCB over the ABC type compared to adults. We have to stress that the number of non-mBL in our cohort is rather small. However, the sub-classification of non-mBL using the molecular categories GCB, ABC or unclassifiable, although successful in adults 11 , might not provide a sufficient molecular explanation for the favourable outcome of pediatric patients.
Nevertheless, as new molecular classification strategies are developing 27 , future studies will provide more insight into similarities and differences between pediatric and adult non-mBL.
In summary, our data presented here suggest that mBL share a molecular profile in children and adults. Nevertheless, the reason for biological differences between both age groups, such as gender distribution, remains elusive. 
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